Eli Lilly (LLY): Congress Asset Management Co reduced its stake -2,355 shares
Congress Asset Management Co reduced its stake in Eli Lilly, per its Q1 2025 13F.
- 198K
- Shares reported · -2,355 vs prior quarter
- 1.2%
- Disclosed portfolio weight
- $164M
- Reported value
- Holdings as of
- Mar 31, 2025
- Filed
- Apr 11, 2025
What stands out in this filing
- 200,639 shares in Q4 2024, 198,284 now (−1.2% in share count).
- Reported at $164M, 1.22% of the portfolio value in this 13F filing.
- 81 other tracked managers reported the same kind of change for Q1 2025.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Jan 8, 2025CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
- Jan 22, 2025CongressDisclosed purchase of LLY — reported range $50,001 - $100,000
- Feb 10, 2025Insider · 1 personInsiders: 3 sales (~$4.3M)
- Feb 10, 2025CongressDisclosed sale of LLY — reported range $50,001 - $100,000
- Feb 13, 2025Insider · 1 personInsiders: 7 sales (~$31.2M)
- Feb 19, 2025Insider · 1 personInsiders: 4 sales (~$8.8M)
- Feb 19, 2025CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
- Feb 20, 2025Insider · 1 personInsiders: 4 sales (~$12.9M)
- Feb 21, 2025Insider · 1 personInsiders: 17 sales (~$87.8M)
- Feb 24, 2025Insider · 1 personInsiders: 14 sales (~$51.8M)
- Feb 25, 2025Insider · 1 personInsiders: 12 sales (~$203.2M)
- Mar 3, 2025Insider · 1 personInsiders: 13 sales (~$204.3M)
- Mar 10, 2025CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
- Mar 13, 2025InsiderOfficer sold ~$818K of LLY shares in the open market
- Apr 7, 2025FDAFDA drug approval: Cyramza
What came next
- Jul 1, 2025FDAFDA drug approval: Kisunla
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Eli Lilly
For Eli Lilly, OQRO holds 4 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports, 5 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LLY page.
How this filing works
Explore the data
Common questions
What does this filing report about Eli Lilly (LLY) stock?
Congress Asset Management Co reduced its stake in Eli Lilly, per its Q1 2025 13F. Now 198K shares, $164M reported value, 1.2% of disclosed portfolio.
When did it happen, and when was it made public?
Holdings as of: Mar 31, 2025. Filed: Apr 11, 2025.
What stands out in this filing?
200,639 shares in Q4 2024, 198,284 now (−1.2% in share count). Reported at $164M, 1.22% of the portfolio value in this 13F filing. 81 other tracked managers reported the same kind of change for Q1 2025.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Eli Lilly recently?
For Eli Lilly, OQRO holds 4 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports, 5 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days. They are listed on the LLY page.
Does this mean LLY stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Eli Lilly
- House Clerk periodic transaction reportNov 18, 2026
- SEC Form 13F-HRNov 16, 2026
- SEC Form 13F-HRNov 16, 2026
- SEC Form 13F-HRNov 13, 2026
- House Clerk periodic transaction reportNov 12, 2026
- House Clerk periodic transaction reportNov 12, 2026
Everything OQRO holds on this company is on its LLY page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
